Patent Ductus Arteriosus: Evidence Based Practice and Standardization of Care (103)

Monday, September 13, 2021

1:45 PM – 2:45 PM CDT

CE: 1

NCC Codes:
RNC-NIC: 2
NNP-BC: 2
RNC-LRN: 3
Pharmacology Credits: .15

Main Presenter(s)

Lisa M. Flowers, MSN, NNP

Neonatal Nurse Practitioner
Mednax Services Inc.
Bosque Farms, New Mexico, United States

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Slides Handouts

Participants should be aware of the following financial/non-financial relationships:

Lisa M. Flowers, MSN, NNP: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Strong evidence favors standardization of care to improve short- and long-term outcomes. The challenge of managing PDA in the preterm population continues to be a clinical practice dilemma. Current evidence management recommendations now sway towards conservative measures with medicinal/surgical interventions reserved for infants with hemodynamically significant PDAs. Determining what constitutes hemodynamically significant and when to treat remains to be debated.

Learning Objectives:

At the conclusion of this presentation, the learner will be able to:

Describe cardiovascular transition to extrauterine life and factors impacting the patency of ductus arteriosus.
Summarize conservative, medicinal, and surgical management of patent ductus arteriosus in the preterm population.
Discuss determinant factors of a hemodynamically significant patent ductus arteriosus.
Recognize results of standardized care and importance of evidence-based practice protocols.